MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 28, 2006; DOI: 10.1124/mol.106.029512


0026-895X/07/7103-667-675$20.00
Mol Pharmacol 71:667-675, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.029512v1
71/3/667    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bauer, B.
Right arrow Articles by Miller, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bauer, B.
Right arrow Articles by Miller, D. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Tumor Necrosis Factor {alpha} and Endothelin-1 Increase P-Glycoprotein Expression and Transport Activity at the Blood-Brain Barrier

Björn Bauer, Anika M. S. Hartz, and David S. Miller

Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina

The ATP-driven drug efflux pump, P-glycoprotein, is a critical and selective element of the blood-brain barrier and a primary impediment to pharmacotherapy of central nervous system (CNS) disorders. Thus, an understanding of how P-glycoprotein function is regulated has the potential to improve CNS therapy. We recently demonstrated rapid (minutes) and reversible inactivation of P-glycoprotein in rat brain capillaries signaled through tumor necrosis factor-{alpha} (TNF-{alpha}) and endothelin-1 (ET-1), components of the brain's innate immune response. In this study, we examined the longer-term consequences of continuous exposure of rat brain capillaries to low levels of TNF-{alpha} and ET-1. Exposing brain capillaries to TNF-{alpha} or ET-1 caused a rapid decrease in P-glycoprotein transport activity with no change in transporter protein expression. This was followed by a 2- to 3-h plateau at the low activity level and then by a sharp increase in both transport activity and protein expression. After 6 h, transport activity and transporter protein expression was double that of control samples. TNF-{alpha} signaled through TNF-R1, which in turn caused ET release and action through ETA and ETB receptors, nitric-oxide synthase, protein kinase C and nuclear factor-{kappa}B (NF-{kappa}B) and finally increased P-glycoprotein expression and transport activity. Assuming similar effects occur in vivo, the present results imply a tightening of the selective blood-brain barrier with chronic inflammation and thus reduced efficacy of CNS-acting drugs that are P-glycoprotein substrates. Moreover, involvement of NF-{kappa}B raises the possibility that other effectors acting through this transcription factor may have similar effects on this key blood-brain barrier transporter.


Received for publication August 1, 2006.

Accepted for publication November 28, 2006.

Address correspondence to: Dr. David S. Miller, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, 111 TW Alexander Dr, PO Box 12233, MD F2–03, Research Triangle Park, NC 27709. E-mail: miller{at}niehs.nih.gov




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
W. Wang, S. Bansal, S. Falk, D. Ljubanovic, and R. Schrier
Ghrelin protects mice against endotoxemia-induced acute kidney injury
Am J Physiol Renal Physiol, October 1, 2009; 297(4): F1032 - F1037.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
H. Xiong, D. Callaghan, A. Jones, J. Bai, I. Rasquinha, C. Smith, K. Pei, D. Walker, L.-F. Lue, D. Stanimirovic, et al.
ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood-Brain Barrier for A{beta}1-40 Peptides
J. Neurosci., April 29, 2009; 29(17): 5463 - 5475.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Ott, G. Fricker, and B. Bauer
Pregnane X Receptor (PXR) Regulates P-Glycoprotein at the Blood-Brain Barrier: Functional Similarities between Pig and Human PXR
J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 141 - 149.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. M. S. Hartz, B. Bauer, M. L. Block, J.-S. Hong, and D. S. Miller
Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier
FASEB J, August 1, 2008; 22(8): 2723 - 2733.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
D. S. Miller, B. Bauer, and A. M. S. Hartz
Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy
Pharmacol. Rev., June 1, 2008; 60(2): 196 - 209.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. Bauer, A. M. S. Hartz, A. Pekcec, K. Toellner, D. S. Miller, and H. Potschka
Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling
Mol. Pharmacol., May 1, 2008; 73(5): 1444 - 1453.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
W. A. Banks, S. Dohgu, J. L. Lynch, M. A. Fleegal-DeMotta, M. A. Erickson, R. Nakaoke, and T. Q. Vo
Nitric Oxide Isoenzymes Regulate Lipopolysaccharide-Enhanced Insulin Transport across the Blood-Brain Barrier
Endocrinology, April 1, 2008; 149(4): 1514 - 1523.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H.-J. Maeng, M.-H. Kim, H.-E. Jin, S. M. Shin, T. Tsuruo, S. G. Kim, D.-D. Kim, C.-K. Shim, and S.-J. Chung
Functional Induction of P-glycoprotein in the Blood-Brain Barrier of Streptozotocin-Induced Diabetic Rats: Evidence for the Involvement of Nuclear Factor-{kappa}B, a Nitrosative Stress-Sensitive Transcription Factor, in the Regulation
Drug Metab. Dispos., November 1, 2007; 35(11): 1996 - 2005.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics